» Articles » PMID: 36338027

Human Bone Marrow Mesenchymal Stem Cell (hBMSCs)-Derived MiR-29a-3p-Containing Exosomes Impede Laryngocarcinoma Cell Malignant Phenotypes by Inhibiting PTEN

Overview
Journal Stem Cells Int
Publisher Wiley
Specialty Cell Biology
Date 2022 Nov 7
PMID 36338027
Authors
Affiliations
Soon will be listed here.
Abstract

Although microRNA-29a-3p was reported to inhibit laryngocarcinoma progression, the potential mechanisms have not been explored clearly. Laryngocarcinoma tissues were collected for analyzing the levels of miR-29a-3p and phosphatase and tensin homolog (PTEN). The miR mimics or inhibitor was transfected into laryngocarcinoma cell lines M4E and Hep2 for the investigation of the biological functions (proliferative, invasion, migratory rates, and apoptotic rates) of this miRNA. The exosomes (Exo) from human bone marrow mesenchymal stem cells (hBMSCs) after the transfection of miR mimics/inhibitor/si-PTEN were isolated and used to stimulate M4E and Hep2 cells. The mouse model was constructed to verify our findings. The miR-29a-3p level was decreased, and PTEN level was elevated in laryngocarcinoma tissues and the cancer cell lines. MiR mimics could inhibit proliferative, invasive migratory rates while promoting apoptotic rates of M4E and Hep2 cells. MiR-29a-3p was enriched in hBMSC-derived Exo, and the Exo from miR-29a-3p mimics transfected hBMSCs could inhibit laryngocarcinoma cell malignant phenotypes and prevent tumor progression . In addition, the direct binding relationship between miR-29a-3p and PTEN in this disease was determined. In conclusion, hBMSC-derived Exo with upregulated miR-29a-3p inhibited laryngocarcinoma progression via regulating PTEN, providing a potential diagnostic and therapeutic target in this disease.

Citing Articles

Isolation and characterization of bone mesenchymal cell small extracellular vesicles using a novel mouse model.

Monroe D, Javeed N, Rowsey J, Ruan M, McCabe C, Piatkowski B J Bone Miner Res. 2024; 39(11):1633-1643.

PMID: 39173022 PMC: 11523127. DOI: 10.1093/jbmr/zjae135.

References
1.
Guo Q, Li Y . [Research on the expression of Survivin and PTEN in laryngeal squamous cell carcinoma transplanted on the back sides of nude mice treated by gold throat tablets]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013; 26(24):1134-7, 1143. View

2.
Esmaeili S, Salari S, Kaveh V, Ghaffari S, Bashash D . Alteration of PPAR-GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells. Mol Genet Genomic Med. 2021; 9(11):e1818. PMC: 8606220. DOI: 10.1002/mgg3.1818. View

3.
Wang Q, Wu S, Gu Y, Liang H, He F, Wang X . RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis. Cell Death Discov. 2022; 8(1):275. PMC: 9170709. DOI: 10.1038/s41420-022-01069-3. View

4.
Zhou Y, Qiu J, Liu S, Wang P, Ma D, Zhang G . CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway. Cancer Med. 2022; 12(1):425-444. PMC: 9844661. DOI: 10.1002/cam4.4919. View

5.
Ragos V, P Fotiades P, Tsiambas E, Peschos D . PTEN in laryngeal carcinomas. J BUON. 2016; 21(4):1024-1025. View